{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T12:10:10Z","timestamp":1750507810567,"version":"3.41.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,21]]},"DOI":"10.7759\/cureus.86483","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:31:06Z","timestamp":1750505466000},"source":"Crossref","is-referenced-by-count":0,"title":["The Management of Thyroid Eye Disease: From Current Practice to Future Perspectives"],"prefix":"10.7759","author":[{"given":"Navnit Kaur","family":"Dhaliwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Razzaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy","volume":"11","author":"Bartalena L","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Front Endocrinol (Lausanne). 2020, 11:615993. 10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves' ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu Y","year":"2014","unstructured":"Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014, 53:353-60. 10.2169\/internalmedicine.53.1518","journal-title":"Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling M","year":"2011","unstructured":"Abraham-Nordling M, Bystr\u00f6m K, T\u00f6rring O, et al.. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011, 165:899-905. 10.1530\/EJE-11-0548","journal-title":"Eur J Endocrinol"},{"key":"ref4","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley GB","year":"1994","unstructured":"Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994, 92:477-588.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05456-x","article-title":"The risk factors for Graves' ophthalmopathy","volume":"260","author":"Cao J","year":"2022","unstructured":"Cao J, Su Y, Chen Z, Ma C, Xiong W. The risk factors for Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2022, 260:1043-54. 10.1007\/s00417-021-05456-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020312","article-title":"Graves' eye disease: clinical and radiological diagnosis","volume":"11","author":"Hutchings KR","year":"2023","unstructured":"Hutchings KR, Fritzhand SJ, Esmaeli B, Koka K, Zhao J, Ahmed S, Debnam JM. Graves' eye disease: clinical and radiological diagnosis. Biomedicines. 2023, 11:10.3390\/biomedicines11020312","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch HB","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, et al.. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022, 11:10.1530\/ETJ-22-0189","journal-title":"Eur Thyroid J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al.. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021, 185:G43-67. 10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_3217_21","article-title":"Update on thyroid eye disease: regional variations in prevalence, diagnosis, and management","volume":"70","author":"Yu CY","year":"2022","unstructured":"Yu CY, Ford RL, Wester ST, Shriver EM. Update on thyroid eye disease: regional variations in prevalence, diagnosis, and management. Indian J Ophthalmol. 2022, 70:2335-45. 10.4103\/ijo.IJO_3217_21","journal-title":"Indian J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_51_21","article-title":"Thyroid eye disease: from pathogenesis to targeted therapies","volume":"12","author":"Yoon JS","year":"2022","unstructured":"Yoon JS, Kikkawa DO. Thyroid eye disease: from pathogenesis to targeted therapies. Taiwan J Ophthalmol. 2022, 12:3-11. 10.4103\/tjo.tjo_51_21","journal-title":"Taiwan J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062045","article-title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy","volume":"14","author":"Cui X","year":"2023","unstructured":"Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy. Front Immunol. 2023, 14:1062045. 10.3389\/fimmu.2023.1062045","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b560","article-title":"Thyroid eye disease","volume":"338","author":"Perros P","year":"2009","unstructured":"Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ. 2009, 338:b560. 10.1136\/bmj.b560","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino G","year":"2022","unstructured":"Barbesino G, Salvi M, Freitag SK. Future projections in thyroid eye disease. J Clin Endocrinol Metab. 2022, 107:S47-56. 10.1210\/clinem\/dgac252","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab034","article-title":"Thyroid eye disease: navigating the new treatment landscape","volume":"5","author":"Dosiou C","year":"2021","unstructured":"Dosiou C, Kossler AL. Thyroid eye disease: navigating the new treatment landscape. J Endocr Soc. 2021, 5:bvab034. 10.1210\/jendso\/bvab034","journal-title":"J Endocr Soc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly GJ","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005, 90:5234-40. 10.1210\/jc.2005-0148","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy","volume":"61","author":"Aktaran S","year":"2007","unstructured":"Aktaran S, Akarsu E, Erba\u011fci I, Araz M, Okumu\u015f S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract. 2007, 61:45-51. 10.1111\/j.1742-1241.2006.01004.x","journal-title":"Int J Clin Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820958335","article-title":"Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application","volume":"11","author":"L\u00e4ngericht J","year":"2020","unstructured":"L\u00e4ngericht J, Kr\u00e4mer I, Kahaly GJ. Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020, 11:2042018820958335. 10.1177\/2042018820958335","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish H","year":"2009","unstructured":"Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009, 94:2708-16. 10.1210\/jc.2009-0376","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6663.1574","article-title":"Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy","volume":"297","author":"Kendall-Taylor P","year":"1988","unstructured":"Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ. 1988, 297:1574-8. 10.1136\/bmj.297.6663.1574","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346732","article-title":"Dose of intravenous steroids and therapy outcome in Graves' orbitopathy","volume":"34","author":"Zang S","year":"2011","unstructured":"Zang S, Ponto KA, Pitz S, Kahaly GJ. Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J Endocrinol Invest. 2011, 34:876-80. 10.1007\/BF03346732","journal-title":"J Endocrinol Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7737","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci C","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, et al.. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001, 86:3562-7. 10.1210\/jcem.86.8.7737","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy","volume":"86","author":"Ye X","year":"2017","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J, Wang J. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. Clin Endocrinol (Oxf). 2017, 86:247-55. 10.1111\/cen.13170","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly GJ","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, et al.. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018, 6:287-98. 10.1016\/S2213-8587(18)30020-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"Kahaly G","year":"1986","unstructured":"Kahaly G, Schrezenmeir J, Krause U, et al.. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986, 16:415-22. 10.1111\/j.1365-2362.1986.tb01016.x","journal-title":"Eur J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy","volume":"321","author":"Prummel MF","year":"1989","unstructured":"Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989, 321:1353-9. 10.1056\/NEJM198911163212002","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u2008\u00d7\u20082 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram R","year":"2018","unstructured":"Rajendram R, Taylor PN, Wilson VJ, et al.. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u2008\u00d7\u20082 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018, 6:299-309. 10.1016\/S2213-8587(18)30021-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad084","article-title":"Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: extended follow-up from the CIRTED Trial","volume":"108","author":"Taylor P","year":"2023","unstructured":"Taylor P, Rajendram R, Hanna S, et al.. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: extended follow-up from the CIRTED Trial. J Clin Endocrinol Metab. 2023, 108:2615-25. 10.1210\/clinem\/dgad084","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-95","article-title":"Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery","volume":"7","author":"Prabhu RS","year":"2012","unstructured":"Prabhu RS, Liebman L, Wojno T, Hayek B, Hall WA, Crocker I. Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery. Radiat Oncol. 2012, 7:95. 10.1186\/1748-717X-7-95","journal-title":"Radiat Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-016-1542-3","article-title":"Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?","volume":"186","author":"Grassi P","year":"2017","unstructured":"Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolont\u00e0 G. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?. Ir J Med Sci. 2017, 186:647-52. 10.1007\/s11845-016-1542-3","journal-title":"Ir J Med Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116945","article-title":"Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves\u2019 orbitopathy","volume":"49","author":"Oeverhaus M","year":"2017","unstructured":"Oeverhaus M, Witteler T, Lax H, Esser J, F\u00fchrer D, Eckstein A. Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves\u2019 orbitopathy. Horm Metab Res. 2017, 49:739-47. 10.1055\/s-0043-116945","journal-title":"Horm Metab Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.025","article-title":"Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology","volume":"129","author":"Sobel RK","year":"2022","unstructured":"Sobel RK, Aakalu VK, Vagefi MR, et al.. Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2022, 129:450-5. 10.1016\/j.ophtha.2021.10.025","journal-title":"Ophthalmology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-019-00846-y","article-title":"Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids","volume":"37","author":"Ma Z","year":"2019","unstructured":"Ma Z, Ozaki H, Ishikawa Y, Jingu K. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids. Jpn J Radiol. 2019, 37:612-8. 10.1007\/s11604-019-00846-y","journal-title":"Jpn J Radiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2011.615455","article-title":"Low dose orbital radiotherapy for thyroid eye disease","volume":"30","author":"Li Yim JF","year":"2011","unstructured":"Li Yim JF, Sandinha T, Kerr JM, Ritchie D, Kemp EG. Low dose orbital radiotherapy for thyroid eye disease. Orbit. 2011, 30:269-74. 10.3109\/01676830.2011.615455","journal-title":"Orbit"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.02.044","article-title":"Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease","volume":"157","author":"Shams PN","year":"2014","unstructured":"Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014, 157:1299-305. 10.1016\/j.ajo.2014.02.044","journal-title":"Am J Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":"Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study","volume":"111","author":"Wakelkamp IM","year":"2004","unstructured":"Wakelkamp IM, Tan H, Saeed P, et al.. Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004, 111:1557-62. 10.1016\/j.ophtha.2003.12.054","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.260","article-title":"Orbital decompression for thyroid eye disease: methods, outcomes, and complications","volume":"32","author":"Jefferis JM","year":"2018","unstructured":"Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM. Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye (Lond). 2018, 32:626-36. 10.1038\/eye.2017.260","journal-title":"Eye (Lond)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000699","article-title":"Thyroid-related orbital decompression surgery: a multivariate analysis of risk factors and outcomes","volume":"33","author":"Wu CY","year":"2017","unstructured":"Wu CY, Niziol LM, Musch DC, Kahana A. Thyroid-related orbital decompression surgery: a multivariate analysis of risk factors and outcomes. Ophthalmic Plast Reconstr Surg. 2017, 33:189-95. 10.1097\/IOP.0000000000000699","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701827","article-title":"Efficacy and side effects of 'swinging eyelid' orbital decompression in Graves' orbitopathy: a proposal for standardized evaluation of diplopia","volume":"20","author":"Paridaens D","year":"2006","unstructured":"Paridaens D, Lie A, Grootendorst RJ, van den Bosch WA. Efficacy and side effects of 'swinging eyelid' orbital decompression in Graves' orbitopathy: a proposal for standardized evaluation of diplopia. Eye (Lond). 2006, 20:154-62. 10.1038\/sj.eye.6701827","journal-title":"Eye (Lond)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/01.PRS.0000069708.70121.67","article-title":"Transcaruncular orbital decompression for management of compressive optic neuropathy in thyroid-related orbitopathy","volume":"112","author":"Chang EL","year":"2003","unstructured":"Chang EL, Bernardino CR, Rubin PA. Transcaruncular orbital decompression for management of compressive optic neuropathy in thyroid-related orbitopathy. Plast Reconstr Surg. 2003, 112:739-47. 10.1097\/01.PRS.0000069708.70121.67","journal-title":"Plast Reconstr Surg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2016.1176049","article-title":"Evaluation of quality of life in patients with Graves\u00b4 ophthalmopathy, before and after orbital decompression","volume":"35","author":"Iacob\u00e6us L","year":"2016","unstructured":"Iacob\u00e6us L, Sahlin S. Evaluation of quality of life in patients with Graves\u00b4 ophthalmopathy, before and after orbital decompression. Orbit. 2016, 35:121-5. 10.1080\/01676830.2016.1176049","journal-title":"Orbit"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.063","article-title":"Oscillopsia after lateral wall orbital decompression","volume":"120","author":"Fayers T","year":"2013","unstructured":"Fayers T, Barker LE, Verity DH, Rose GE. Oscillopsia after lateral wall orbital decompression. Ophthalmology. 2013, 120:1920-3. 10.1016\/j.ophtha.2013.01.063","journal-title":"Ophthalmology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.11.022","article-title":"Risk factors for reoperation after strabismus surgery among patients with thyroid eye disease","volume":"238","author":"Hwang B","year":"2022","unstructured":"Hwang B, Heo H, Lambert SR. Risk factors for reoperation after strabismus surgery among patients with thyroid eye disease. Am J Ophthalmol. 2022, 238:10-5. 10.1016\/j.ajo.2021.11.022","journal-title":"Am J Ophthalmol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1080204","article-title":"Update on the surgical management of Graves' orbitopathy","volume":"13","author":"Baeg J","year":"2022","unstructured":"Baeg J, Choi HS, Kim C, Kim H, Jang SY. Update on the surgical management of Graves' orbitopathy. Front Endocrinol (Lausanne). 2022, 13:1080204. 10.3389\/fendo.2022.1080204","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4103\/ojo.OJO_133_2016","article-title":"Prognostic preoperative factors for successful outcome of surgery in horizontal strabismus","volume":"10","author":"Kumari N","year":"2017","unstructured":"Kumari N, Amitava AK, Ashraf M, Grover S, Khan A, Sonwani P. Prognostic preoperative factors for successful outcome of surgery in horizontal strabismus. Oman J Ophthalmol. 2017, 10:76-80. 10.4103\/ojo.OJO_133_2016","journal-title":"Oman J Ophthalmol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi M","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, et al.. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015, 100:422-31. 10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan MN","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015, 100:432-41. 10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras JV","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al.. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018, 195:181-90. 10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study","volume":"14","author":"Boutzios G","year":"2023","unstructured":"Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, Tzioufas AG. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study. Front Endocrinol (Lausanne). 2023, 14:1186105. 10.3389\/fendo.2023.1186105","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al.. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017, 376:1748-61. 10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al.. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020, 382:341-52. 10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study","volume":"129","author":"Douglas RS","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, et al.. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study. Ophthalmology. 2022, 129:438-49. 10.1016\/j.ophtha.2021.10.017","journal-title":"Ophthalmology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas RS","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, et al.. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023, 109:25-35. 10.1210\/clinem\/dgad637","journal-title":"J Clin Endocrinol Metab"},{"key":"ref53","article-title":"Preclinical pharmacokinetics of VRDN-003, a next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease","volume":"64","author":"Dickinson B","year":"2023","unstructured":"Dickinson B, Foster K, Bedian V. Preclinical pharmacokinetics of VRDN-003, a next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease. Investigative Ophthalmol Visual Sci. 2023, 64:4043.","journal-title":"Investigative Ophthalmol Visual Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.2125","article-title":"6461 VRDN-003, a full antagonist antibody to the igf-1 receptor for thyroid eye disease (TED): safety and pharmacokinetic results of subcutaneous administration in healthy volunteers","volume":"8","author":"Foster K","year":"2024","unstructured":"Foster K, Dickinson B, Matthew A, Vijayaraghavan J, Michalsky C, Bedian V. 6461 VRDN-003, a full antagonist antibody to the igf-1 receptor for thyroid eye disease (TED): safety and pharmacokinetic results of subcutaneous administration in healthy volunteers. J Endocr Soc. 2024, 8:bvae163.2125. 10.1210\/jendso\/bvae163.2125","journal-title":"J Endocr Soc"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-019-0121-9","article-title":"Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity","volume":"10","author":"Furmaniak J","year":"2019","unstructured":"Furmaniak J, Sanders J, Clark J, Wilmot J, Sanders P, Li Y, Rees Smith B. Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity. Auto Immun Highlights. 2019, 10:11. 10.1186\/s13317-019-0121-9","journal-title":"Auto Immun Highlights"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial","volume":"96","author":"Furmaniak J","year":"2022","unstructured":"Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022, 96:878-87. 10.1111\/cen.14681","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn Inhibitor, Batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly GJ","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, et al.. Proof-of-concept and randomized, placebo-controlled trials of an FcRn Inhibitor, Batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023, 108:3122-34. 10.1210\/clinem\/dgad381","journal-title":"J Clin Endocrinol Metab"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy","volume":"29","author":"Marcinkowski P","year":"2019","unstructured":"Marcinkowski P, Hoyer I, Specker E, et al.. A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy. Thyroid. 2019, 29:111-23. 10.1089\/thy.2018.0349","journal-title":"Thyroid"},{"key":"ref59","article-title":"Paving the way for small-molecule drug discovery","volume":"13","author":"Ma YS","year":"2021","unstructured":"Ma YS, Xin R, Yang XL, et al.. Paving the way for small-molecule drug discovery. Am J Transl Res. 2021, 13:853-70.","journal-title":"Am J Transl Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369836-the-management-of-thyroid-eye-disease-from-current-practice-to-future-perspectives","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:31:07Z","timestamp":1750505467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369836-the-management-of-thyroid-eye-disease-from-current-practice-to-future-perspectives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.86483","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,21]]}}}